Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
Antigens, Neoplasm
/ analysis
Biomarkers, Tumor
/ analysis
Carcinoma, Transitional Cell
/ chemistry
DNA-Binding Proteins
/ analysis
Endonucleases
/ analysis
Humans
Keratin-19
/ analysis
Neoplasm Proteins
/ analysis
Prognosis
Receptor, Fibroblast Growth Factor, Type 3
/ analysis
Trypsin Inhibitor, Kazal Pancreatic
/ analysis
Tumor Suppressor Protein p53
/ analysis
Urinary Bladder Neoplasms
/ chemistry
biomarkers
bladder cancer
prognosis
tumor markers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 May 2020
09 May 2020
Historique:
received:
16
04
2020
revised:
04
05
2020
accepted:
05
05
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice.
Identifiants
pubmed: 32397531
pii: ijms21093360
doi: 10.3390/ijms21093360
pmc: PMC7247579
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
DNA-Binding Proteins
0
Keratin-19
0
Neoplasm Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
antigen CYFRA21.1
0
Trypsin Inhibitor, Kazal Pancreatic
50936-63-5
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
ERCC1 protein, human
EC 3.1.-
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Chem. 2002 Aug;48(8):1206-9
pubmed: 12142374
Cell Cycle. 2013 Apr 1;12(7):1022-9
pubmed: 23466706
Scand J Gastroenterol. 1986 Dec;21(10):1275-80
pubmed: 3810002
Eur Urol. 2017 Jun;71(6):961-969
pubmed: 28069289
Curr Opin Urol. 2012 Sep;22(5):390-6
pubmed: 22825458
Crit Rev Oncol Hematol. 2017 Dec;120:120-126
pubmed: 29198325
Tumour Biol. 2015 May;36(5):3137-45
pubmed: 25854170
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
Iran J Pathol. 2019 Spring;14(2):148-155
pubmed: 31528172
Int J Oncol. 2006 Jan;28(1):95-101
pubmed: 16327984
J Urol. 2010 Jan;183(1):68-75
pubmed: 19913255
J Urol. 2012 Jan;187(1):310-4
pubmed: 22099989
Annu Rev Pathol. 2016 May 23;11:149-74
pubmed: 26907529
J Urol. 2015 Nov;194(5):1456-62
pubmed: 26162296
Mol Cell. 2014 Jun 19;54(6):960-74
pubmed: 24857548
J Cancer. 2019 Oct 15;10(25):6207-6216
pubmed: 31772653
Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86
pubmed: 25107571
J Coll Physicians Surg Pak. 2017 Apr;27(4):232-236
pubmed: 28492153
PLoS One. 2010 Nov 03;5(11):e13821
pubmed: 21072204
Eur Urol. 2009 Mar;55(3):650-7
pubmed: 18584939
Cancers (Basel). 2018 Apr 01;10(4):
pubmed: 29614760
BMC Cancer. 2016 Sep 01;16:704
pubmed: 27586786
Genome Integr. 2012 Apr 11;3(1):3
pubmed: 22494821
Nat Rev Clin Oncol. 2018 Apr;15(4):203-204
pubmed: 29255240
Future Oncol. 2010 Nov;6(11):1735-49
pubmed: 21142660
Scand J Clin Lab Invest Suppl. 1991;207:5-9
pubmed: 1780691
World J Urol. 2012 Dec;30(6):785-94
pubmed: 21739120
J Clin Oncol. 2006 Aug 1;24(22):3664-71
pubmed: 16877735
Am J Clin Oncol. 1996 Jun;19(3):271-7
pubmed: 8638540
Clin Chem. 1996 Oct;42(10):1634-8
pubmed: 8855147
Eur Urol. 2013 Oct;64(4):639-53
pubmed: 23827737
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Urol Int. 2011;87(4):420-8
pubmed: 22041857
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Hum Mol Genet. 2013 Feb 15;22(4):795-803
pubmed: 23175443
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
J Urol. 2009 Sep;182(3):907-13
pubmed: 19616250
World J Surg Oncol. 2016 Apr 30;14:137
pubmed: 27129876
Ren Fail. 1998 Mar;20(2):295-302
pubmed: 9574455
Urology. 2008 Nov;72(5):1159-63
pubmed: 18514770
Genet Mol Res. 2015 Apr 27;14(2):3921-31
pubmed: 25966163
J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6
pubmed: 16217281
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
N Engl J Med. 2006 Sep 7;355(10):983-91
pubmed: 16957145
Sci Rep. 2014 Mar 07;4:4313
pubmed: 24603753
Anticancer Res. 2015 Sep;35(9):4915-21
pubmed: 26254388
J Pathol. 2007 Sep;213(1):91-8
pubmed: 17668422
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Cancer Biomark. 2019;26(3):281-289
pubmed: 31594208
Bladder Cancer. 2016 Jul 27;2(3):301-317
pubmed: 27500198
Oncotarget. 2016 Oct 11;7(41):67435-67448
pubmed: 27611947
Tumour Biol. 2016 Oct;37(10):14329-14330
pubmed: 27448817
Cancer Res. 2018 May 1;78(9):2233-2247
pubmed: 29440146
ORL J Otorhinolaryngol Relat Spec. 1997 Mar-Apr;59(2):106-14
pubmed: 9166881
Cancer. 1993 Mar 15;71(6):1982-8
pubmed: 8443749
Clin Chim Acta. 2012 Dec 24;414:93-100
pubmed: 22944145
J Pathol. 2018 Nov;246(3):331-343
pubmed: 30043421
Anticancer Res. 2009 Oct;29(10):4281-5
pubmed: 19846987
Ther Adv Urol. 2016 Jun;8(3):215-33
pubmed: 27247631
Int J Cancer. 1983 Jun 15;31(6):711-4
pubmed: 6190763
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Oncol Lett. 2017 Sep;14(3):3817-3824
pubmed: 28927152
Adv Urol. 2012;2012:429213
pubmed: 22899908
Expert Opin Ther Targets. 2017 Apr;21(4):401-414
pubmed: 28281901
Chest. 2005 Mar;127(3):978-83
pubmed: 15764785
Urology. 2003 Aug;62(2):249-53
pubmed: 12893328
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Scand J Clin Lab Invest. 2001;61(6):431-41
pubmed: 11681532
Genes Dev. 2009 Mar 15;23(6):675-80
pubmed: 19261747
J Urol. 2017 Jun;197(6):1410-1418
pubmed: 28049011
Int J Cancer. 1997 Jun 20;74(3):330-4
pubmed: 9221814
Mol Clin Oncol. 2013 May;1(3):403-410
pubmed: 24649183
Int J Cancer. 2015 Oct 1;137(7):1621-9
pubmed: 25809917
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Urol Oncol. 2014 Jan;32(1):49.e23-31
pubmed: 24360661
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
BMC Cancer. 2012 May 22;12:187
pubmed: 22616552
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Cancer. 2002 Jun 1;94(11):2914-22
pubmed: 12115379
Cancer Med. 2015 Jan;4(1):75-83
pubmed: 25354498
Eur Urol. 2005 Sep;48(3):424-31
pubmed: 15963628
Diagn Pathol. 2019 Sep 14;14(1):105
pubmed: 31521181
Clin Chem. 1989 May;35(5):869-71
pubmed: 2470538
Cancer Treat Rev. 2007 Feb;33(1):9-23
pubmed: 17084534
J Pathol. 2009 May;218(1):104-12
pubmed: 19156776